Medical Condition News

RSS

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Investigators in The Cancer Genome Atlas (TCGA) Research Network have uncovered a connection between how tumor cells use energy from metabolic processes and the aggressiveness of the most common form of kidney cancer, clear cell renal cell carcinoma (ccRCC).

24 Jun 2013

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a post-hoc pooled analysis showing patients with type 2 diabetes and mild renal impairment treated with JANUVIA- (sitagliptin) 100 mg once-daily achieved similar blood sugar reductions as those treated with the sulfonylureas glipizide or glimepiride, with significantly fewer events of hypoglycemia (low blood sugar), and with weight loss instead of weight gain.

24 Jun 2013

Robotic animals can help improve quality of life for people with dementia, says research

Robotic animals can help to improve the quality of life for people with dementia, according to new research. A study has found that interacting with a therapeutic robot companion made people with mid- to late-stage dementia less anxious and also had a positive influence on their quality of life.

24 Jun 2013

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Sanofi announced today that the first Phase 3 study results for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus.

24 Jun 2013

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Elcelyx Therapeutics announced today that clinical study results confirm that the primary site of action of Type 2 diabetes medicine metformin is in the lower bowel rather than in the circulation.

24 Jun 2013

Psychology professor receives grant from Hogg Foundation to study ethnic differences in children's depression

Dr. Chrystyna Kouros, an assistant professor in the Department of Psychology at Southern Methodist University, received a $19,250 grant from the Hogg Foundation for Mental Health to examine ethnic differences in the identification of and attributions about children's depression symptoms.

24 Jun 2013

Researchers identify biological roots of migraine from large-scale genome study

In the largest study of migraines, researchers have found 5 genetic regions that for the first time have been linked to the onset of migraine. This study opens new doors to understanding the cause and biological triggers that underlie migraine attacks.

24 Jun 2013

Study recommends depression screening In AF clinics

Electrophysiologists (EPs) rate the quality of life of patients with Paroxysmal atrial fibrillation (AF) significantly better than the patients themselves do, with the greatest level of disagreement about mental health.

24 Jun 2013

New method allows assessment of direct stimulation effects on electric activity of human brain

Neuroscientists at the University of Tübingen have become the first to record neuromagnetic activity in the millisecond-by-millisecond range while the brain of a human subject was under stimulation by electric current. Electric brain stimulation has successfully been used in the treatment of neurological and psychiatric disorders for many decades.

24 Jun 2013

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Boehringer Ingelheim today announced the submission of an application to the European Medicines Agency (EMA) for use of Pradaxa (dabigatran etexilate) for the treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE.

24 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

CeQur SA, a company focused on the development and commercialization of simple insulin delivery devices, announced that comprehensive data from a study of the company's PaQ Insulin Delivery Device will be presented today and tomorrow at the American Diabetes Association 73rd Scientific Sessions in Chicago, IL. The data suggest that PaQ can reduce known barriers to insulin therapy among people with type 2 diabetes, potentially improving their glycemic control.

24 Jun 2013

Discovery of cells movement inside body may provide information to scientists about disease mechanism s

A new discovery about how cells move inside the body may provide scientists with crucial information about disease mechanisms such as the spread of cancer or the constriction of airways caused by asthma.

24 Jun 2013

EHRA White Book reports on current status of arrhythmia treatments in 55 ESC member countries2

The first European data on lead extraction was released today by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). The information is published in the EHRA White Book 20131, launched at EHRA EUROPACE 2013 in Athens, Greece, during 23-26 June.

24 Jun 2013

Compared with Medicaid enrollees, low-income uninsured adults are less likely to have chronic conditions

Compared with adults already enrolled in Medicaid, low-income uninsured adults who may be eligible for Medicaid under the Affordable Care Act were less likely to have chronic conditions such as hypertension, diabetes, and hypercholesterolemia, although those with 1 of these conditions were less likely to be aware they had it or to have the disease controlled, according to a study in the June 26 issue of JAMA. The study is being released early to coincide with its presentation at the AcademyHealth annual research meeting.

24 Jun 2013

Researchers discover reason behind failed anti-cancer therapy

Researchers at the Hebrew University of Jerusalem and in California have achieved a breakthrough in understanding how and why a promising anti-cancer therapy has failed to achieve hoped-for success in killing tumor cells.

24 Jun 2013

Joslin Diabetes Center, Sanofi US present results from multicultural outreach program

Sanofi US collaborated with Joslin Diabetes Center on a successful, multicultural outreach pilot that was overseen and funded by Sanofi US with Joslin as its partner in providing clinical and behavioral educational materials and training based on their award-winning On the Road diabetes program.

24 Jun 2013

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia. ST10 is a novel form of ferric iron taken orally.

24 Jun 2013

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Astellas Pharma Europe Ltd., the European Headquarters of Tokyo-based Astellas Pharma Inc. (TSE:4503), and Medivation, Inc. announced that following the regulatory review process by the European Medicines Agency (EMA) and a positive opinion from the Committee for Medicinal Products for Human Use on April 25, 2013, the European Commission (EC) has granted the marketing authorization for XTANDI™ (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.

24 Jun 2013

Medical Condition News

Investigators uncover connection between tumor metabolic process and progression of kidney cancer

Patients with type2 diabetes, renal impairment have less hypoglycemia with JANUVIA compared to sulfonylurea

Robotic animals can help improve quality of life for people with dementia, says research

Sanofi reports Phase 3 study of insulin U300 shows better blood sugar control than Lantus

Elcelyx's study shows NewMet has better glucose-lowering effects than metformin in type2 diabetic patients

Psychology professor receives grant from Hogg Foundation to study ethnic differences in children's depression

Researchers identify biological roots of migraine from large-scale genome study

Study recommends depression screening In AF clinics

New method allows assessment of direct stimulation effects on electric activity of human brain

Boehringer submits application to EMA for use of Pradaxa for treatment of acute DVT, PE

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

New data suggest PaQ device can reduce known barriers to insulin therapy among people with type 2 diabetes

Discovery of cells movement inside body may provide information to scientists about disease mechanism s

EHRA White Book reports on current status of arrhythmia treatments in 55 ESC member countries2

Compared with Medicaid enrollees, low-income uninsured adults are less likely to have chronic conditions

Researchers discover reason behind failed anti-cancer therapy

Joslin Diabetes Center, Sanofi US present results from multicultural outreach program

Shield Therapeutics recruits patients for ST10 Phase 3 study for treating iron-deficient anaemia

EC grants marketing authorization for XTANDI capsules for treating advanced prostate cancer

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

How electrical engineering ensures accurate calibration and patient safety

Latest News